Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...
Jan 20 (Reuters) - Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results